17th Clinical Trials on Alzheimer's Disease (CTAD), 2024
We are thrilled to invite you to an exclusive opportunity to engage with our leading experts during the upcoming Clinical Trials on Alzheimer's Disease (CTAD) 2024. The CTAD is a conference focused entirely on Alzheimer's Disease Therapeutic Trials, with key leaders in Alzheimer's Disease research from industry and academia coming together to form partnerships aimed at accelerating the development of effective treatments to fight the disease.
Don’t miss out on this unique opportunity to connect with our cross-functional neuroscience team and get insights on customized strategies to help accelerate your timelines and get your therapy to market faster.
Connect with one of our key leaders
Laurentiu Gutiu, MD
Executive Medical Director - TA Lead Neuroscience and Ophthalmology
Dr. Gutiu is a board-certified neurologist with more than 15 years of clinical experience in a hospital setting across a wide range of neurological and psychiatric indications. He spent 10 years in academia as Assistant Professor of Neurology and attended doctoral courses in neuropharmacology. His 28 years of clinical research experience includes roles as an investigator, medical monitor and medical leadership positions spanning Phase I-IV studies.
He has broad range of experience across product modalities, including biologics and cell and gene therapies as well as medical expertise in neuro and psychiatric diseases, including, but not limited to, neurodegenerative, pain, neuromuscular and demyelinating.
Based in Germany.